Login to Your Account



Karo Bio Stock Drops, Safety Issues Sink Eprotirome Trial

By Cormac Sheridan
Staff Writer

Wednesday, February 15, 2012
Shares in Karo Bio AB plunged more than 66 percent Tuesday on news that the company was terminating a Phase III pivotal trial of its lead drug eprotirome, after a toxicology study in dogs indicated that long-term exposure could result in cartilage damage.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription